InVivo Therapeutics Corporation
One Broadway
14th Floor
Cambridge
Massachusetts
02142
United States
Tel: 617-475-1520
Website: http://www.invivotherapeutics.com/
Email: Info@invivotherepaeutics.com
362 articles about InVivo Therapeutics Corporation
-
InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
10/7/2022
InVivo Therapeutics Holdings Corp. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company’s common stock.
-
InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel
7/13/2022
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Officer and General Counsel.
-
InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery
6/8/2022
InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery.
-
InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study
6/2/2022
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has completed enrollment in the INSPIRE 2.0 Study for patients with acute spinal cord injury.
-
InVivo Therapeutics Announces Reverse Stock Split - Apr 14, 2022
4/14/2022
InVivo Therapeutics Holdings Corp. announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock.
-
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference
1/6/2022
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming virtual H.C. Wainwright BioConnect Conference, which runs from January 10 – 13, 2022.
-
InVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company’s Complete HDE Submission
7/13/2021
InVivo Therapeutics Holdings Corp. today announced the acceptance by the U.S. Food and Drug Administration (FDA) of its preclinical module, which is one of three individual modules required for the Company’s humanitarian device exemption (HDE) application.
-
InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
7/6/2021
InVivo Therapeutics Holdings Corp. today reminded stockholders that their virtual Annual Meeting of Stockholders is scheduled for Friday, July 16, 2021 at 11 a.m., ET.
-
InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
3/12/2021
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference, which runs from March 17 – March 19 from 9:00 am – 5:00 pm
-
It’s estimated there are more than 17,000 new cases of spinal cord injuries each year, which can cause permanent damage in patients.
-
InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine
2/16/2021
InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine Manuscript Details Complete Six-Month INSPIRE 1.0 Primary Endpoint Study Results
-
InVivo Therapeutics Announces Closing of $15.0 Million Public Offering
10/26/2020
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $0.80 per share (or pre-funded warrant) and associated warrant. The gro
-
InVivo Therapeutics Announces Pricing of $15.0 Million Public Offering
10/22/2020
InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $ 0.80 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering
-
InVivo Therapeutics Announces Presentation at the Upcoming H.C Wainwright Virtual Global Investment Conference
9/11/2020
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference.
-
InVivo Therapeutics Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4/17/2020
InVivo Therapeutics Holdings Corp. (NVIV) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 1,715,240 shares of its common stock at a purchase price of $1.75 per share
-
InVivo Therapeutics Announces Closing of $7.0 Million Public Offering
3/11/2020
InVivo Therapeutics Holdings Corp. announced the closing of its previously announced public offering of 2,545,455 shares of common stock, together with warrants to purchase up to 2,545,455 shares of common stock at a combined effective price to the public of $2.75 per share and associated warrant.
-
InVivo Therapeutics Announces Pricing of $7.0 Million Public Offering
3/6/2020
InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 2,545,455 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 2,545,455 shares of common stock at a combined effective price to the public of $2.75 per share (or pre-funded warrant) and associated warrant.
-
InVivo Therapeutics Announces Reverse Stock Split
2/3/2020
InVivo Therapeutics Holdings Corp. announced a 1-for-30 reverse stock split of its common stock and a proportionate reduction in its authorized common stock.
-
InVivo Therapeutics Announces Pricing of Public Offering of Common Stock at $0.12 per share
11/21/2019
InVivo Therapeutics Holdings Corp. announced the pricing of a public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share.
-
InVivo Therapeutics Announces Proposed Public Offering of Common Stock
11/18/2019
InVivo Therapeutics Holdings Corp. announced that it has commenced a proposed public offering of shares of its common stock, par value $0.00001 per share.